UMPIRE - Trial of an implantable device for continuous monitoring of epileptic seizure activity.

Focal and Generalised Epilepsy

Epileptic seizures result from abnormal electrical activity in the brain, which can be monitored by electroencephalography (EEG).  EEG monitoring may improve the detection, treatment and potentially prediction of seizures, but the equipment is cumbersome and the test is time consuming.  As a result, long term seizure monitoring is often impractical and seizures are often missed during routine evaluations.  The UMPIRE study evaluates the safety of Minder, an experimental device, implanted under the scalp for continuous monitoring of seizure activity.  Brain activity data recorded in the study will be analysed to evaluate its utility for detecting epileptic activity and seizures.

Category
Trial Status
Active, not recruiting
Trial Phase
Medical Device Pilot Study
Trial contact details
Contact Person
Delphine Lévy-Bencheton
What you need to know

Who can take part?

  • People aged 18 to 75, diagnosed with focal or generalised epilepsy
  • People with a minimum of 2 seizures per month (focal or generalized epilepsy)
  • Female participants of childbearing potential must avoid pregnancy during the study
  • Not open to participants with another implanted neurostimulation device, including vagus nerve stimulation, deep brain stimulation or cochlear implants

What is involved for you?

Participants will have the Minder device surgically implanted behind one ear, with an electrode implanted under the scalp along the back of the head. Participants are given a wearable device to transmit EEG data to a mobile phone. They will also have the following procedures and tests:

  • Blood tests
  • Electrocardiogram
  • Physical exam and vital signs
  • CT Scan
  • Two 7-day video EEG monitoring sessions during the 6 month study
  • Keep a seizure diary

Trial dates

This trial is accepting participants until July 2023.

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.

23

May

Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|